In conclusion, our study provides evidence that NMN administration in the presence of elevated plasma levels of FFA, as in obesity or type 2 diabetes, results in substantially improved glucose tolerance by significantly decreasing insulin clearance and partially protecting against FFA-induced β cell dysfunction in vivo. This evidence concerns the gene INS and Obesity.